Maccura Biotechnology Co.Ltd (SHE:300463)
China · Delayed Price · Currency is CNY 11.61
+0.04 (0.35%)
Sep 29, 2025, 3:04 PM CST
SHE:300463 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 2,324 | 2,525 | 2,862 | 3,568 | 3,934 | 3,665 | Upgrade |
Other Revenue | 20.73 | 23.39 | 33.95 | 40.18 | 46.47 | 39.12 | Upgrade |
| 2,345 | 2,549 | 2,896 | 3,608 | 3,981 | 3,704 | Upgrade | |
Revenue Growth (YoY) | -16.07% | -11.98% | -19.75% | -9.35% | 7.47% | 14.92% | Upgrade |
Cost of Revenue | 1,083 | 1,173 | 1,384 | 1,712 | 1,740 | 1,796 | Upgrade |
Gross Profit | 1,262 | 1,376 | 1,512 | 1,897 | 2,240 | 1,908 | Upgrade |
Selling, General & Admin | 798.13 | 789.95 | 805.79 | 749.75 | 756.1 | 636.98 | Upgrade |
Research & Development | 331.3 | 323.15 | 324.17 | 273.22 | 207.27 | 202.07 | Upgrade |
Other Operating Expenses | 28.53 | 10.65 | 11.73 | 22.02 | 28.77 | 21.48 | Upgrade |
Operating Expenses | 1,170 | 1,114 | 1,180 | 1,081 | 999.91 | 880.9 | Upgrade |
Operating Income | 92.71 | 262.16 | 331.6 | 815.54 | 1,240 | 1,027 | Upgrade |
Interest Expense | -20.85 | -22.12 | -33.53 | -35.06 | -59.27 | -68.19 | Upgrade |
Interest & Investment Income | 6.56 | 9.33 | 18.62 | 24.15 | 5.4 | 4.33 | Upgrade |
Earnings From Equity Investments | - | - | - | - | - | 0.99 | Upgrade |
Currency Exchange Gain (Loss) | 0.12 | 0.16 | 1.11 | 5.33 | -2.19 | -4.5 | Upgrade |
Other Non Operating Income (Expenses) | -3.57 | -1.41 | -2.38 | 3.2 | -3 | -4.73 | Upgrade |
EBT Excluding Unusual Items | 74.97 | 248.12 | 315.42 | 813.17 | 1,181 | 954.69 | Upgrade |
Impairment of Goodwill | -94.11 | -94.11 | - | - | - | - | Upgrade |
Gain (Loss) on Sale of Investments | -7.23 | 2.15 | -7.08 | -9.1 | - | - | Upgrade |
Gain (Loss) on Sale of Assets | -1.3 | -6.73 | -4.17 | -4.12 | -4.05 | 0.94 | Upgrade |
Asset Writedown | -52.29 | -36.54 | -9.54 | -22.46 | -26.01 | -5.31 | Upgrade |
Other Unusual Items | 9.88 | 11.77 | 10.73 | 11.59 | 35.81 | 19.44 | Upgrade |
Pretax Income | -70.08 | 124.65 | 305.37 | 789.08 | 1,187 | 969.77 | Upgrade |
Income Tax Expense | -22.89 | 5.89 | 0.69 | 87.38 | 184.88 | 148.41 | Upgrade |
Earnings From Continuing Operations | -47.19 | 118.76 | 304.68 | 701.71 | 1,002 | 821.35 | Upgrade |
Minority Interest in Earnings | 6.31 | 8.04 | 7.94 | 6.48 | -45.64 | -27.44 | Upgrade |
Net Income | -40.88 | 126.81 | 312.62 | 708.18 | 956.6 | 793.92 | Upgrade |
Net Income to Common | -40.88 | 126.81 | 312.62 | 708.18 | 956.6 | 793.92 | Upgrade |
Net Income Growth | - | -59.44% | -55.86% | -25.97% | 20.49% | 51.15% | Upgrade |
Shares Outstanding (Basic) | 609 | 606 | 609 | 604 | 553 | 554 | Upgrade |
Shares Outstanding (Diluted) | 609 | 613 | 612 | 608 | 557 | 557 | Upgrade |
Shares Change (YoY) | -0.61% | 0.01% | 0.77% | 9.16% | -0.11% | -0.05% | Upgrade |
EPS (Basic) | -0.07 | 0.21 | 0.51 | 1.17 | 1.73 | 1.43 | Upgrade |
EPS (Diluted) | -0.07 | 0.21 | 0.51 | 1.17 | 1.72 | 1.42 | Upgrade |
EPS Growth | - | -59.44% | -56.19% | -32.18% | 20.62% | 51.23% | Upgrade |
Free Cash Flow | -274.15 | -329.22 | 23.61 | -144.52 | 1,015 | 592.73 | Upgrade |
Free Cash Flow Per Share | -0.45 | -0.54 | 0.04 | -0.24 | 1.82 | 1.06 | Upgrade |
Dividend Per Share | 0.104 | 0.104 | 0.154 | 0.349 | 0.471 | 0.431 | Upgrade |
Dividend Growth | -32.48% | -32.48% | -55.89% | -25.86% | 9.30% | 127.83% | Upgrade |
Gross Margin | 53.83% | 53.99% | 52.20% | 52.57% | 56.28% | 51.51% | Upgrade |
Operating Margin | 3.95% | 10.29% | 11.45% | 22.60% | 31.16% | 27.72% | Upgrade |
Profit Margin | -1.74% | 4.98% | 10.80% | 19.63% | 24.03% | 21.44% | Upgrade |
Free Cash Flow Margin | -11.69% | -12.92% | 0.81% | -4.00% | 25.50% | 16.00% | Upgrade |
EBITDA | 434.22 | 582.02 | 626.55 | 1,068 | 1,463 | 1,232 | Upgrade |
EBITDA Margin | 18.52% | 22.84% | 21.64% | 29.60% | 36.75% | 33.26% | Upgrade |
D&A For EBITDA | 341.51 | 319.86 | 294.94 | 252.56 | 222.54 | 205.22 | Upgrade |
EBIT | 92.71 | 262.16 | 331.6 | 815.54 | 1,240 | 1,027 | Upgrade |
EBIT Margin | 3.95% | 10.29% | 11.45% | 22.60% | 31.16% | 27.72% | Upgrade |
Effective Tax Rate | - | 4.72% | 0.23% | 11.07% | 15.57% | 15.30% | Upgrade |
Revenue as Reported | 2,345 | 2,549 | 2,896 | 3,608 | 3,981 | 3,704 | Upgrade |
Advertising Expenses | - | 58.56 | 104.69 | 96.23 | 114.73 | 87.37 | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.